TITLE

Prophylaxis Failure Is Associated with a Specific Pneumocystis carinii Genotype

AUTHOR(S)
Hauser, Philippe M.; Sudre, Philippe; Nahimana, Aimable; Francioli, Patrick
PUB. DATE
October 2001
SOURCE
Clinical Infectious Diseases;10/1/2001, Vol. 33 Issue 7, p1080
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To investigate the possible association between Pneumocystis carinii types and various clinical and demographic parameters, we used molecular typing to analyze 93 bronchoalveolar lavage specimens from patients with P. carinii pneumonia (PCP). Multivariate regression analysis revealed an association between being infected with a specific P. carinii genotype and receiving anti-PCP prophylaxis (odds ratio, 4.4; 95% confidence interval, 1.0--18.6;P=.05), although no association with a specific drug was detected.
ACCESSION #
5522453

 

Related Articles

  • DELAYING THE ONSET OF ILLNESS. Cohan, Gary R. // Advocate;2/8/94, Issue 648, p34 

    Reports that prophylaxis against Pneumocystis carinnii infection may delay the onset of the first AIDS-related illness.

  • Pneumocystis carinii pneumonia.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p26 

    Reports on the US Food and Drug Administration's approval on the marketing of a suspension form of atovaquone in the treatment of pneumocystis carinii pneumonia. Advantages and convenience; Dosage.

  • Current management practices in the treatment of Pneumocystis carinii pneumonia (PCP). Blanchet, Kevin D. // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p116 

    Presents a dialogue on current management practices in the treatment of Pneumocystis carinii pneumonia (PCP). Prophylaxis and compliance; Treatment of mild PCP; Patient management issues.

  • Pneumocystis carinii pneumonia prophylaxis reduces mortality, costs.  // Formulary;Sep95, Vol. 30 Issue 9, p544 

    Presents an abstract of the article `The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia,' by J.E. Gallant, S.M. McAvinue, R.D. Moore et al, which appeared in the 1995 issue of `Chest' periodical.

  • PCP PREVENTION ALERT. Delaney, Martin // Advocate;11/19/91, Issue 590, p37 

    Reports on the medical alert received by physicians from the U.S. National Institutes of Health concerning the prevention of second bouts of Pneumocystis carinii pneumonia. Call for monthly treatments with aerosol pentamidine; Superiority of the oral use of two common antibiotics.

  • Pentamidine Oral Inhalation.  // AHFS Consumer Medication Information;Oct2019, p1 

    Pentamidine is an anti-infective agent that helps to treat or prevent pneumonia caused by the organism Pneumocystis carinii. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

  • RACE AND TREATMENT ACCESS.  // Advocate;6/28/94, Issue 658, p58 

    Reports on racial disparities in the administration of antiretroviral therapy and prophylactic treatment for Pneumocystis carinii pneumonia. Access to and standards of care.

  • Improved Treatment For Pneumocystis. Helquist, Michael // Advocate;10/13/87, Issue 483, p23 

    Reports on the efficacy of aerosol pentamidine against pneumocystis carinii pneumonia in persons with AIDS. Absence of side effects; Reduction in average hospital stay.

  • Prophylaxis Recommendations for Pneumocystis. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;3/25/2002, Vol. 15 Issue 3, p110 

    Reports the indication of primary prophylaxis of Pneumocystis for patients with history of Pneumocystis carinii pneumonia. Efficacy of trimethoprim-sulfamethoxazole (TMP-SMX); Considerations in discontinuing primary and secondary prophylaxis; Dosage for TMP-SMX.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics